Pharma Focus Asia

Daiichi Sankyo’s FLT3 Inhibitor Quizartinib Treats Relapsed/Refractory FLT3-ITD AML

Daiichi Sankyo Company, Limited announced quizartinib, an investigational FLT3 inhibitor, for the treatment of adult patients with relapsed/refractory FLT3-ITD Acute Myeloid Leukemia (AML).

Quizartinib is the first FLT3 inhibitor to enhance overall survival as an oral, single agent compared to chemotherapy in patients with relapsed/refractory AML with FLT3-ITD, an underlying driver of this subtype of AML.

It helps to bring new treatment options to patients with serious diseases. The inhibitor is the result of the pivotal phase 3 QuANTUM-R study of quizartinib.

QuANTUM-R is the first randomised phase 3 study to show that a FLT3 inhibitor, quizartinib, prolongs overall survival as an oral, single agent compared to chemotherapy in patients with relapsed/refractory FLT3-ITD AML.
 
The safety profile observed in QuANTUM-R appears consistent with that observed at similar doses in the quizartinib clinical development program.

The frequency of treatment-emergent adverse events was comparable between patients who received single agent quizartinib (n=241) and those who received salvage chemotherapy (n=94).

The most common adverse events (>30 percent, any Grade) in patients treated with quizartinib included nausea, thrombocytopenia, fatigue, musculoskeletal pain, pyrexia, anemia, neutropenia, febrile neutropenia, vomiting and hypokalemia.

QuANTUM-R, a pivotal, global, phase 3, open-label randomized study had enrolled 367 patients with FLT3-ITD-mutated AML who were refractory to or in relapse (with duration of remission of six months or less) following standard first-line AML therapy with or without HSCT.

Patients were randomised in a 2:1 ratio to receive either single agent oral quizartinib or salvage chemotherapy.

Latest Issue
Get instant
access to our latest e-book
MFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Gibco Adherent Kidney Media PanelCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024ISPE Singapore Affiliate Conference & Exhibition 2024Rehab Expo 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024